ENZON ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL FOR ATG-FRESENIUS S

Enzon Pharmaceuticals has announced the first patient has been dosed in a clinical trial for ATG-Fresenius S for the prevention of acute organ rejection in patients receiving lung transplantation.

The clinical trial is a double-blind, multicenter, randomized study comparing two different dosing regimens of ATG-Fresenius S plus the standard post-transplant triple immunosuppressive regimen to a group treated with only the standard triple immunosuppressive regimen in patients undergoing lung transplantation.

The primary clinical endpoint is defined as the occurrence of acute transplant rejection, graft loss, or death within six months after transplant.

ATG-FRESENIUS S is a polyclonal antibody preparation used for T-lymphocyte suppression in organ transplant patients to prevent organ graft rejection.